XML 86 R62.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Revenue $ 22.4 $ 76.5 $ 211.2 $ 101.8
Less:        
Total research and development expense 68.6 93.7 159.4 178.0
General and administrative expense 25.3 31.3 51.9 55.6
Income tax expense (0.3) 0.2 (0.2) 0.3
Interest income, net 10.3 13.6 22.0 27.6
Segment net (loss) income (61.2) (35.2) 21.7 (104.6)
Reportable Segment        
Segment Reporting Information [Line Items]        
Revenue 22.4 76.5 211.2 101.8
Less:        
Non program-specific external expense 11.1 13.5 25.0 29.6
Compensation and related personnel expense (including stock-based compensation) 28.4 36.3 65.3 74.6
Other research and development expense 4.3 3.2 7.4 6.2
Total research and development expense 68.6 93.7 159.4 178.0
General and administrative expense 25.3 31.3 51.9 55.6
Other segment expense, net 0.3 0.1 0.4 0.1
Income tax expense (0.3) 0.2 (0.2) 0.3
Interest income, net 10.3 13.6 22.0 27.6
Segment net (loss) income (61.2) (35.2) 21.7 (104.6)
Reportable Segment | Vepdegestrant ARV-471        
Less:        
Program-specific external expense 15.1 25.1 39.2 44.1
Reportable Segment | ARV-102        
Less:        
Program-specific external expense 3.8 1.7 10.3 3.0
Reportable Segment | ARV-393        
Less:        
Program-specific external expense 2.5 1.7 5.1 2.9
Reportable Segment | ARV-806        
Less:        
Program-specific external expense 1.7 0.2 2.6 0.3
Reportable Segment | Bavdegalutamide (ARV-110)        
Less:        
Program-specific external expense 0.9 2.5 2.0 4.1
Reportable Segment | Luxdegalutamide (ARV-766)        
Less:        
Program-specific external expense 0.0 9.5 0.0 13.2
Reportable Segment | Other programs        
Less:        
Program-specific external expense $ 0.8 $ 0.0 $ 2.5 $ 0.0